Maunuksela E L, Olkkola K T, Korpela R
Children's Hospital, Helsinki, Finland.
Ann Clin Res. 1987;19(5):359-63.
To study the effect of intravenous indomethacin on blood pressure, heart rate, body temperature and post-operative bleeding we performed a double-blind, placebo-controlled study on 100 operated children, aged 1-16 years. At the end of operation intravenous indomethacin 0.35 mg/kg followed by an infusion of 0.07 mg/kg/h for 24 h combined with standard doses of morphine according to clinical needs resulted in better postoperative analgesia than morphine alone. During the two first hours the systolic and diastolic blood pressure and ventilation rate did not differ between the groups. The heart rate was significantly lower (p less than 0.001) in the indomethacin group. Indomethacin did not prolong the bleeding time. Mild to moderate bleeding was observed in 13 indomethacin--and five placebo-treated patients (p less than 0.05). The bleeding did not, however, require any intervention. The mean body temperature did not differ between the two groups in the evening following the operation, but was significantly lower (p less than 0.01) on the first postoperative morning in the indomethacin group. Six patients (12%) in the placebo group had fever over 38 degrees C and paracetamol was administered to four of them. Clinically diminished diuresis was not observed. Since prophylactic indomethacin infusion improves the postoperative analgesia in children and no clinically important unwanted effects were seen, it may be used in children, over one year of age in whom non-steroidal anti-inflammatory drugs are not contraindicated.
为研究静脉注射吲哚美辛对血压、心率、体温及术后出血的影响,我们对100名年龄在1至16岁的接受手术的儿童进行了一项双盲、安慰剂对照研究。手术结束时,静脉注射吲哚美辛0.35mg/kg,随后以0.07mg/kg/h的速度输注24小时,并根据临床需要联合标准剂量的吗啡,其术后镇痛效果优于单独使用吗啡。在最初的两个小时内,两组的收缩压、舒张压和通气率没有差异。吲哚美辛组的心率显著更低(p<0.001)。吲哚美辛未延长出血时间。在接受吲哚美辛治疗的13名患者和接受安慰剂治疗的5名患者中观察到轻度至中度出血(p<0.05)。然而,出血不需要任何干预。术后当晚两组的平均体温没有差异,但在术后第一个早晨,吲哚美辛组的体温显著更低(p<0.01)。安慰剂组有6名患者(12%)体温超过38摄氏度,其中4名患者使用了对乙酰氨基酚。未观察到临床上明显的利尿减少。由于预防性输注吲哚美辛可改善儿童术后镇痛效果,且未观察到临床上重要的不良反应,因此它可用于一岁以上且非甾体类抗炎药无禁忌的儿童。